Cheryl Wellington, Canada

University of British Columbia Pathology and Laboratory Medicine
Dr. Cheryl Wellington is Professor in the Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Center for Brain Health at the University of British Columbia. She is also Principal Investigator at the International Collaboration on Repair Discoveries at Vancouver General Hospital and Associate Member of the UBC School of Biomedical Engineering. Dr. Wellington’s research interests are highly multidisciplinary with major efforts in the fields of Alzheimer’s Disease (AD) and Traumatic Brain Injury (TBI). With respect to both AD and TBI programs, her laboratory is the leading Canadian site for research on blood biomarkers using the Quanterix single molecule array (Simoa) platform. Her work on AD focuses mainly on how lipoproteins affect AD pathogenesis, with major projects focused on apolipoprotein E (apoE). For the AD program, her laboratory uses a combination of animal models and in vitro platforms, including pioneering a human-based 3D tissue engineered model of perfusable cerebral vessels surrounded by astrocytes and neurons. Along with Dr. Peter Cripton, a Mechanical Engineer, Dr. Wellington developed the CHIMERA (Closed Head Model of Engineered Rotational Acceleration) animal model of TBI that is currently operational for mice, rats and ferrets. Dr. Wellington is now also leading major efforts to understand the neurological consequences of COVID-19. Dr. Wellington holds multiple leadership positions in both the dementia and neurotrauma communities, including the Canadian Traumatic Brain Injury Research Consortium, the International Traumatic Brain Injury Research Consortium, the Canadian Consortium for Neurodegeneration in Aging, and Cure Alzheimer Fund ApoE Consortium.

Presenter of 5 Presentations

LIVE DISCUSSION & Q&A: WHY ARE THE VASCULAR COMPONENTS AND BLOOD-BRAIN/BLOOD-RETINA BARRIERS OF THE BRAIN AND EYE IMPORTANT CONTRIBUTORS TO THE TIPPING POINT BETWEEN HEALTH AND DISEASE?

BIOENGINEERED VASCULAR MODELS FOR DEMENTIA (INVOLVING ENDOTHELIA, SMOOTH MUSCLE, AND ASTROCYTES)

Session Type
PRE CONFERENCE SYMPOSIUM
Date
09.03.2021, Tuesday
Session Time
10:00 - 14:50
Room
Pre-Conference 1
Lecture Time
13:10 - 13:30
Session Icon
On-Demand and Live Q&A

THE ROLE OF HIGH DENSITY LIPOPROTEINS IN THE VASCULAR CONTRIBUTIONS TO ALZHEIMER’S DISEASE

Session Type
SYMPOSIUM
Date
10.03.2021, Wednesday
Session Time
12:00 - 14:00
Room
On Demand Symposia B
Lecture Time
12:00 - 12:15
Session Icon
On-Demand

Abstract

Aims

To determine the physiological functions of human high-density lipoprotein (HDL) particles on human endothelial cells cultured alone or in context with other cells of the neurovascular unit.

Abstract Body

Aims: To determine the physiological functions of human high-density lipoprotein (HDL) particles on human endothelial cells cultured alone or in context with other cells of the neurovascular unit.

Methods: We used primary and human iPSC cells in standard monoculture and in a 3-dimensional bioengineered arterial model of the perfused human cerebrovasculature to study cerebral amyloid angiopathy (CAA) as measured by Aβ deposition and transport, and Aβ-induced endothelial inflammation measured by monocyte binding.

Results: HDL vascular Aβ accumulation independently of its principal binding protein, scavenger receptor (SR)-BI, in contrast to the SR-BI-dependent mechanism by which HDL prevents Aβ-induced vascular inflammation. HDL also reduces CAA through four mechanisms: i) altering Aβ binding to collagen-I, ii) forming a complex with Aβ that maintains its solubility, iii) diminishing collagen-I expression by smooth-muscle cells (SMC), and iv) attenuating Aβ uptake in SMC perhaps by reducing LRP1 expression. Finally, HDL particles enriched in apolipoprotein (apo)E appear to be the major drivers of these effects.

Conclusions: Circulating HDL, particularly HDL particles with apoE, may have beneficial effects on the cerebrovasculature, acting from the lumen to facilitate Ab egress from the brain and reduce cerebrovascular inflammation.

Methods

We used primary and human iPSC cells in standard monoculture and in a 3-dimensional bioengineered arterial model of the perfused human cerebrovasculature to study cerebral amyloid angiopathy (CAA) as measured by Aβ deposition and transport, and Aβ-induced endothelial inflammation measured by monocyte binding.

Results

HDL vascular Aβ accumulation independently of its principal binding protein, scavenger receptor (SR)-BI, in contrast to the SR-BI-dependent mechanism by which HDL prevents Aβ-induced vascular inflammation. HDL also reduces CAA through four mechanisms: i) altering Aβ binding to collagen-I, ii) forming a complex with Aβ that maintains its solubility, iii) diminishing collagen-I expression by smooth-muscle cells (SMC), and iv) attenuating Aβ uptake in SMC perhaps by reducing LRP1 expression. Finally, HDL particles enriched in apolipoprotein (apo)E appear to be the major drivers of these effects.

Conclusions

Circulating HDL, particularly HDL particles with apoE, may have beneficial effects on the cerebrovasculature, acting from the lumen to facilitate Aβ egress from the brain and reduce cerebrovascular inflammation.

Hide